Selecta links with Takeda on next generation gene therapies
Massachusetts, USA-based Selecta Biosciences (Nasdaq: SELB) today announced that it has entered into a strategic licensing agreement with Japan’s Takeda Pharmaceutical (TYO: 4502) to develop targeted, next-generation gene therapies for two indications within the field of lysosomal storage disorders.
The collaboration leverages Selecta’s ImmTOR platform to enable redosing of transformative therapies, and the news pushed the firm’s shares up as much as 4.6% to $4.38 in early trading.
Selecta’s ImmTOR platform enhances transgene expression and addresses adeno-associated virus (AAV) vector immunogenicity constraints to deliver transformative therapies, the company noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze